Enanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.
Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections. Its lead RSV program, EDP-938, is an orally administered inhibitor designed to block viral replication and is being evaluated in Phase 2 clinical trials for both adult and pediatric populations. In addition to RSV, Enanta is advancing preclinical candidates against hepatitis B virus (HBV) and other respiratory pathogens, seeking to apply its structure-based drug design approach to a broader array of infectious diseases.
Founded in 1997 by a team of chemists and virologists, Enanta has established collaborative relationships with large pharmaceutical firms to accelerate the development and commercialization of its antiviral compounds. These partnerships have provided non-dilutive funding and clinical development support, while allowing Enanta to retain rights to key programs in certain territories.
Under the leadership of President and Chief Executive Officer Jay R. Luly, the company continues to expand its scientific capabilities and manufacturing collaborations. Enanta maintains research facilities in Massachusetts and works with contract development and manufacturing organizations to advance its pipeline. With a focus on unmet medical needs in viral diseases, Enanta aims to bring novel oral therapies to patients worldwide.
